James Malter, PhD
University of Wisconsin-Madison Medical School
Treatment of Alzheimer's Disease with mGluR5 Inhibitor
Award: $96,427
Duration: 2008 - 2009
Walter Schmidt, PhD
University of Georgia
Enhancing IDE-mediated destruction of Abeta and other amyloiogenic peptides
Award: $50,000
Duration: 2008 - 2009
Tara Spires-Jones, DPhil
Massachusetts General Hospital
Sirtuins as modifiers of neurodegeneration in a mouse model of
frontotemporal dementia
Award: $85,000
Duration: 2008 - 2009
Daniel Laskowitz, PhD
Duke University Medical Center
A novel apoE-derived therapeutic reduces AD pathology
Award: $178,449
Duration: 2007 - 2009
Luciano D'Adamio, MD, PhD
RemeGenix, Inc.
Commercialization of BR12 peptides for AD
Award: $100,000
Duration: 2008 - 2009
Nazneen Dewji, PhD
University of California, San Diego
Novel Therapeutic Approaches for the Treatment of Alzheimer's Disease
Award: $75,000
Duration: 2008 - 2009
Michelle Block, PhD
Virginia Commonwealth University
NADPH Oxidase as a Therapeutic Target in Alzheimer's Disease
Award: $163,036
Duration: 2008 - 2009
Einar M. Sigurdsson, PhD
NYU School of Medicine
Clearance of Pathological Tau Conformers
Award: $125,000
Duration: 2008 - 2009
Mark Tuszynski, MD, PhD
University of California, San Diego
Preventing Neuronal Loss in the Non-Human Primate Cortex
Award: $150,000
Duration: 2006 - 2009
Yung-Feng Liao, PhD
Academia Sinica
Genetic Modifiers of gamma-Secretase-mediated selective cleavage of amyloid
precursor protein in Alzheimer's disease
Award: $50,000
Duration: 2008 - 2009
Alvin Terry, PhD
Medical College of Georgia
New Drugs for Treating the Cognitive Deficits and Psychotic Symptoms of
Alzheimer's Disease
Award: $75,000
Duration: 2008 - 2009
Larry Baum, PhD
The Chinese University of Hong Kong
Testing 17-AAG for Treating Fronto-Temporal Dementia
Award: $50,000
Duration: 2008 - 2009
Shaila Handattu, PhD
University of Alabama at Birmingham
HDL Modulation, Inflammation and Alzheimer's Disease
Award: $89,016
Duration: 2008 - 2009
Louis B. Hersh, PhD
University of Kentucky
Neprilysin and Peripheral Clearance of Amyloid Peptides
Award: $100,000
Duration: 2008 - 2009
Iliya M. Lefterov, MD,
PhD
University of Pittsburgh
Identifying LXR activators for Potential Treatment of Alzheimer's Disease
Award: $150,000
Duration: 2008 - 2009
Horacio Saragovi, PhD
Lady Davis Institute for Medical Research, S.M.B.D.-Jewish General Hospital
Efficacy of TrkA-targeted neuroprotective drugs in a mouse model of AD
Award: $100,000
Duration: 2008 - 2009
A. Claudio Cuello, MD,
DSc, FRSC
McGill University, Dept. of Pharmacology and Therapeutics
A novel combined experimental therapy in an Alzheimer's transgenic model
Award: $100,000
Duration: 2008 - 2009
Ben Bahr, PhD
University of Connecticut
In vitro testing of new lysosomal modulatory drugs for reducing tau
aggregates in a hippocampal slice model
Award: $65,000
Duration: 2008 - 2009
Gabriela Chiosis, PhD
Sloan-Kettering Institute
Development of Hsp90 inhibitors as novel therapeutics for AD
Award: $100,000
Duration: 2007-2008
Paul Lombroso, MD
Yale University Medical School
Screening for inhibitors of STEP
Award: $100,000
Duration: 2007 - 2008
Raz Yirmiya, PhD
The Hebrew University of Jerusalem
The role of brain interleukin-1 in Alzheimer's disease associated memory
disturbances
Award: $40,000
Duration: 2007 - 2008
Edward Nemergut, MD
University of Virginia
The use of high-dose intravenous erythropoletin to prevent cognitive
dysfunction following cardiopulmonary bypass
Award: $94,972
Duration: 2007 - 2008
Yousef Al-Abed, PhD
The Feinstein Institute for Medical Research North Shore
CNI-1493
inhibits Abeta production and prevents plaque formation in an animal model of
Alzheimer's Disease
Award: $75,000
Duration: 2007 - 2008
Michael S. Wolfe, PhD
Brigham and Women's Hospital
Selective Amyloid-Lowering Agents
Award: $130,000
Duration: 2007 - 2008
Frank M. Longo, MD, PhD
PharmatrophiX
Inhibition of Alzheimer-related neurodegeneration by small molecule
neurotrophin receptor ligands
Award: $300,000
Duration: 2006 -2007
Generation and Optimization of NO mimetics for Treatment of Alzheimer’s Disease–Part 2
Award: $130,000
Duration: 2006 – 2007
Jari Koistinaho, MD, PhD
University of Kuopio
The transcription factor Nrf2 mediated pathway as a
therapeutic target in Alzheimer's disease
Award: $80,000
Duration: 2007 - 2008
Michael Hutton, Ph.D.
Mayo Clinic
Development of a cell-based platform for drug
discovery in tauopathy
Award: $100,000
Duration: 2006 - 2007
Jianhua Zhou, Ph.D.
University of Massachusetts Medical School
Distal cis-elements and compounds that regulate tau
splicing
Award: $50,000
Duration: 2007 - 2008
Ken A. Witt, Ph.D.
Southern Illinois University - Edwardsville
Somatostatin Agonist Treatment for Cognitive Aging
and Dementia
Award: $100,000
Duration: 2007
D. Martin Watterson, PhD
Northwestern University
Gene-Regulating Protein Kinase Inhibitors as
Potential AD Therapeutics
Award: $130,000
Duration: 2007
Jack T. Rogers, PhD
Massachusetts General Hospital
Alzheimer's Drugs to APP translation and alpha
secretase coactivation
Award: $80,000
Duration: 2007 - 2009
Juan Sanchez-Ramos, MD, PhD
University of South Florida
Bone Marrow-Mobilizing Agents for Alzheimer's
Disease
Award: $70,802
Duration: 2007 - 2008
The Effect of ApoE Mimetic
Therapeutic Peptide in a Murine Model of AD.
Award: $102,364
Duration: 2004 – 2005
An ApoE-Derived
Therapeutic Improves AD Pathology in a Murine Model following Head Injury –
Year 2
Award: $93,449
Duration: 2005 - 2006
John Cashman, Ph.D.
Human Biomolecular Research Institute
New Immune Modulators of Alzheimer's Disease
Award: $65,000
Duration: 2007
James J. Lah, MD, PhD
Emory University
Targeted Discovery of LR11/SorLA-Based Alzheimer
Therapeutics
Award: $100,000
Duration: 2007 - 2008
Sidney Strickland, Ph.D.
The Rockefeller University
Screening for PAI-1 inhibitors to increase plasmin
AlphaBeta- degrading activity
Award: $100,000
Duration: 2006 - 2007
Dale E. Bredesen, Ph.D
Buck Institute for Age Research
Screening for Alzheimer's Therapeutics Based on a
Novel Target
Award: $50,000
Duration: 2004
Award: $50,000
Duration: 2006 - 2007
Gary Gibson, Ph.D.
Weill Medical College of Cornell University
Tests of therapies aimed at mitochondrial deficits
in neurodegenerative diseases
Award: $80,000
Duration: 2006 - 2007
Roberta Diaz Brinton, Ph.D.
University of Southern California
Allopregnanolone as a Neurogenic Factor for Recovery
of Neurons in Alzheimer's Disease
Award: $274,659
Duration: 2005 - 2008
Eckhard Mandelkow, Ph.D.
Max-Planck-Unit for Structural Molecular
Biology
Search for Inhibitors of Tau Aggregation
Award: $377,500
Duration: 2003 - 2007
Search for Inhibitors of Tau Aggregation
Award: $159,500
Duration: 2005 - 2006
Eva-Maria Mandelkow, MD, PhD
Max-Planck-Unit for Structural Molecular
Biology
MARK kinase inhibtors
Award: $100,000
Duration: 2007 - 2008
Paul Gard, Ph.D.
University of Brighton
Cognitive-enhancing effects of angiotensin IV: an
investigation of molecular mechanisms
Award: $16,000
Duration: 2007 - 2008
David Weinshenker, Ph.D.
Emory University
Noradrenergic treatments for Alzheimer's disease
Award: $90,887
Duration: 2006 - 2007
Barry Forman, Ph.D.
City of Hope
Synthetic LXRBeta Ligands in the Treatment of
Alzheimer's Disease
Award: $75,000
Duration: 2006 - 2007
Novel Therapeutics Targeting Neuroinflammation
Award: $140,000
Duration: 2005 – 2006
Search for Inhibitors of
Tau Aggregation
Award: $159,500
Duration: 2005 – 2006
NGF Small Molecule Mimetics: Preclinical Studies
Award: $150,000
Duration: 2005 – 2006
An ApoE-Derived Therapeutic Improves AD
Pathology in a Murine Model following Head Injury - Year 2
Award: $93,449
Duration: 2005 – 2006
Siew Yeen Chai, PhD
Howard Florey Institute
Victoria, Australia
IRAP - Novel Target for the Development
of Memory-Enhancing Agents
Award: $82,000
Duration: 2005 – 2006
Anne Cataldo, PhD
McLean Hospital/Harvard Medical School
Belmont, MA
A Novel Method of Cell-Mediated Therapy
for Alzheimer’s Disease
Award: $75,000
Duration: 2005 – 2006
Berislav Zlokovic, MD, Ph.D
University of Rochester
Blockers of RAGE/amyloid-beta interaction at the
blood brain barrier.
Award: $295,723
Duration: 2004 - 2007
Nicholas Webster, Ph.D.
Veteran's Medical Research Foundation
Development of cell-permeable NGF mimetics
Award: $130,000
Duration: 2006 - 2008
Greg R. J. Thatcher, Ph.D.
University of Illinois at Chicago
Generation and optimization of NO mimetics for
treatment of Alzheimer's Disease
Award: $260,000
Duration: 2004 - 2007
Steven Schreiber, M.D.
University of California, Irvine
Efficacy of the Histone Deacetylase Inhibitor, SAHA,
in AD Transgenic Mice- A Proof-of-Concept Study
Award: $130,000
Duration: 2006 - 2007
Moussa B.H. Youdim, PhD
Technion
Development and molecular mechanism of neuroprotective activity of novel
bifucntional Cholineterase-monoamine oxidase inhibitor-iron chelators for
the treatment of Alzheimer's disease and Lewy body disease
Award: $195,000
Duration: 2006 - 2008
Stuart A. Lipton, PhD
Neuromolecular, Inc.
Mill Valley, CA
Drug Development Plan for Nitro-Memantine
(Memantine-ONO 2) Derivatives
Award: $244,700
Duration: 2004 – 2006
June Kinoshita
Alzheimer Research
Forum Foundation
Waltham, MA
Alzheimer Cheminformatics Resource
Award: $60,275
Duration: 2004 – 2006
Michael Hutton, PhD
Mayo Clinic Jacksonville
Jacksonville, FL
In Vivo Testing of Compounds that Block
the Development of Neurofibrillary Tau Pathology
Award: $196,662
Duration: 2004 – 2006
The TGF-Beta Pathway as a Therapeutic Target to Treat Alzheimer’s Disease
Award: $152,300
Duration: 2004 – 2005
Marta Weinstock-Rosin, PhD
Hebrew University
Medical Centre
Jerusalem, Israel
Award for Major Scientific Achievement in Drug Discovery and
Development for Alzheimer’s Disease
Award: $100,000
Duration: 2004 – 2005
Michael L. Shelanski, MD, PhD
Columbia University
New York, NY
Pharmacological Reversal of the Behavioral and Electrical
Sequelae of A-Beta Deposition
Award: $50,000
Duration: 2004 – 2005
Leonard Petrucelli, PhD
Mayo Clinic Jacksonville
Jacksonville, FL
Hsp70 Activity and Tau A Therapeutic Target
Award: $125,000
Duration: 2004 – 2005
BDNF Small Molecule Mimetics
Award: $162,500
Duration: 2004 – 2005
Screening for Alzheimer’s Therapeutics Based on a
Novel Target
Award: $100,000
Duration: 2004
In Vivo Analysis of Effects of Microtubule-Stabilizing
Drugs in Tau Mutant Mice
Award: $258,352
Duration: 2003 – 2006
Wolfgang J. Streit, PhD University of Florida Gainesville, FL
Role of Fractalkine in Regulating Neuronmicroglia Interactions
Award: $126,492
Duration: 2003 – 2005
Small Molecule Drug Discovery Targeted To The Alzheimer’s APP-mRNA 5’
Untranslated Region
Award: $100,000
Duration: 2003 – 2005
Ram Ramabhadran, PhD
Tranzyme Pharma, Inc.
Research Triangle Park, NC
Cell Culture Models and Animal Models of
Alzheimer’s Disease
Award: $493,550
Duration: 2003 – 2005
Novel Properties of Analogs of Choline for the
Treatment of Neurodegenerative Diseases
Award: $259,651
Duration: 2003 – 2005
Columbia University
New York, NY
Calpain Inhibitor: A Treatment of Alzheimer’s Disease - Part 2
Award: $88,205
Duration: 2003 – 2005
Tony Wyss-Coray, PhD
Stanford University
Stanford, CA
The TGF-Beta Pathway as a Therapeutic Target to Treat Alzheimer’s Disease
Award: $152,232
Duration: 2003 – 2004
Drug Discovery: Estrogen Related Compounds in Mouse Models of Alzheimer’s Disease
Award: $90,000
Duration: 2003 – 2004
Efficacy of Oral Heparin Treatment for
Alzheimer’s Disease
Award: $98,563
Duration: 2003 – 2004
Yasuji Matsuoka, PhD
Georgetown University
Medical Center
Washington, DC
Development of Abeta-Binding Agents for Abeta
Sequestration Therapy
Award: $98,500
Duration: 2003 – 2004
Edward D. Levin, PhD
Duke University Medical Center
Durham, NC
EC-SOD Protection from Aging-Induced
Cognitive Deficits Due to Oxidative Stress
Award: $52,775
Duration: 2003 – 2004
Grant A. Krafft, PhD
Acumen Pharmaceuticals, Inc.
Glenview, IL
High Throughput Screens for ADDL-Blocker Compounds
Award: $133,493
Duration: 2003 – 2004
Novel Glycosaminoglycan (GAG) Precursors as Anti-Amyloid Agents - Part 2
Award: $191,220
Duration: 2003 – 2004
Luc Buee, PhD
INSERM U422 (French National Institute for Health and Medical Research)
Lille, France
Towards Pin1 Inhibitors
in the Treatment of
Alzheimer’s Disease
Award: $85,000
Duration: 2003 – 2004
Joel L. Sussman, PhD
The Weizmann Institute
of Science
Rehovot, Israel
Structural and Functional Analysis of Beta Secretase as
a Potential Target for Therapeutic Intervention in Alzheimer’s Disease
Award: $312,555
Duration: 2002 – 2005
Manfred Windisch, PhD
JSW-Research Forschungslabor GmbH
Graz, Austria
Development of a New Treatment for Alzheimer’s Disease and Parkinson’s Disease using Anti-Aggregatory Beta-Synuclein Derived Peptides
Award: $260,000
Duration: 2002 – 2004
Founders Program: Studies on Human Memapsin 2 (Beta-Secretase): Drug Design for Alzheimer’s Disease
Award: $250,000
Duration: 2002 – 2004
Beka Solomon, PhD
Tel Aviv University
Tel Aviv, Israel
A Novel Approach Towards Vaccination Against Alzheimer Beta-Amyloid Peptide
Award: $100,000
Duration: 2002 – 2004
Rebekah Loy, PhD
University of Rochester
Rochester, NY
Valproate and Lithium to Inhibit Tau Pathophysiology
Award: $115,309
Duration: 2002 – 2004
Dora M. Kovacs, PhD
Massachusetts General Hospital
Charlestown, MA
Effect of ACAT Inhibition
on A-Beta Levels in PS1-APP Transgenic Mice
Award: $125,000
Duration: 2002 – 2004
Natural Product Extracts
that Reduce A-Beta Peptide Accumulation
Award: $250,000
Duration: 2002 – 2004
Jordan Tang, PhD
Zapaq, Inc.
Oklahoma City, OK
Studies on Human Memapsin (Beta-Secretase): Prerequisite
of Drug Design for
Alzheimer’s Disease
Award: $500,000
Duration: 2002 – 2003
Marcos A. Marques, PhD
ApoLogic, Inc.
Cincinnati, OH
Novel Drug Target in Alzheimer’s Disease
Award: $145,395
Duration: 2002 – 2003
Allon Therapeutics, Inc.
Vancouver, BC
Canada
Alzheimer’s Disease
Biotech Program
Award: $253,100
Duration: 2002 – 2003
Dale E. Bredesen, PhD
Buck Institute for
Age Research
Novato, CA
Development of Drugs for a New Therapeutic Target in Alzheimer’s Disease
Award: $100,000
Duration: 2002 – 2003
Etienne-Emile Baulieu, PhD
MAPREG
Le Kremlin-Bicetre
France
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases
Award: $150,000
Duration: 2002 – 2003
Alan Faden, MD
Georgetown University
School of Medicine Washington, DC
Modulation of Beta-Amyloid Induced Neuronal Apoptosis
by Selective Activation
of Metabotrophic
Glutamate Receptors
Award: $100,000
Duration: 2001 – 2005
D. Martin Watterson, PhD
Northwestern University Medical School
Chicago, IL
Ligands that Suppress Neuroinflammatory Responses
Award: $476,278
Duration: 2001 – 2004
Duane L. Venton, PhD
University of Illinois, Chicago
Chicago, IL
A Combinatorial Search for Beta-Cyclodextrins to Abate the Neurotoxicity of Amyloid-Beta-Peptide in Alzheimer’s Disease
Award: $311,916
Duration: 2001 – 2004
Rudolph E. Tanzi, PhD
Massachusetts
General Hospital
Charlestown, MA
Small Molecule Therapeutics
for Alzheimer’s Disease
Award: $340,000
Duration: 2001 – 2004
Simon Melov, PhD
Buck Institute for Age Research
Novato, CA
Potential Therapeutics for Alzheimer’s Disease
Award: $97,987
Duration: 2001 – 2004
Stephen M. Strittmater, PhD
Yale University Medical School
New Haven, CT
Nogo Antagonists in Axon Regeneration and Plasticity
Award: $267,928
Duration: 2001 – 2003
Sidney Strickland, PhD
The Rockefeller University New York, NY
Analysis of the Role to tPA
and Plasmino(gen) in Alzheimer’s Disease
Award: $256,480
Duration: 2001 – 2003
Alzheimer’s Disease Drug Discovery Targeted to the APP-mRNA 5’Untranslated Region
Award: $96,734
Duration: 2001 – 2003
Elliott Richelson, MD
Mayo Clinic Jacksonville
Jacksonville, FL
Peptide Nucleic Acids
Targeted to the Amyloid Precursor Protein
Award: $200,000
Duration: 2001 – 2003
Sebastian Lazareno, PhD
Medical Research
Council Technology
London, England
Development of Selective Allosteric
Enhancers at Human Muscarinic Receptors
Award: $473,626
Duration: 2001 – 2003
Jerry Buccafusco, PhD
Prime Behavior Testing Laboratories, Inc.
Augusta, GA
A Computer-Assisted Cognitive Test
Battery for Aged Monkey
Award: $112,947
Duration: 2001 – 2003
Joseph K. Belanoff, MD
Corcept Therapeutics, Inc.
Menlo Park, CA
Slowing the Progression
of Cognitive Decline in Alzheimer’s Disease Using Mifepristone
Award: $462,929
Duration: 2001 – 2003
Tim Tully, PhD
Helicon Therapeutics
Cold Spring Harbor, NY
CREB and the Discovery of Cognitive Enhancers
Award: $238,780
Duration: 2001 – 2002
Kenneth Kosik, MD
Brigham and Women’s Hospital
Boston, MA Identifying Drugs that Inhibit Kinase-Induced
Dissociation of Tau from Microtububles
Award: $130,000
Duration: 2001 – 2002
Christopher B. Eckman, PhD
Mayo Clinic Jacksonville
Jacksonville, FL
Herbal Extracts that Reduce A-Beta
Peptide Accumulation
Award: $127,567
Duration: 2001 – 2002
Ming-Ming Zhou, PhD
Mount Sinai Medical Center
Rochester, NY
Structure-based Functional Design of Antagonists for Glutamate Receptors
Award: $600,621
Duration: 2000 – 2004
Frank M. Longo, MD, PhD
University of North Carolina School of Medicine
Chapel Hill, NC
Alzheimer’s Therapeutics: Neurotrophin Small
Molecule Mimetics
Award: $521,517
Duration: 2000 – 2004
NGF Small Molecule
Mimetics: Preclinical Studies
Award: $150,000
Duration: 2005 - 2006
Khalid Iqbal, PhD
NY State Institute for
Basic Research in Developmental Disabilities
New York, NY
Screening Assays to Inhibit Alzheimer Neurofibrillary Degeneration
Award: $528,869
Duration: 2000 – 2004
Suzana Petanceska, PhD
Nathan Kline Institute
Orangeburg, NY
Pharmacogenetic Effects of Human apoE on the
Amyloid-Reducing Activity of Cholesterol Lowering Drugs in a
Transgenic Mouse Model for Alzheimer’s Disease
Award: $360,742
Duration: 2000 – 2003
Robert Kisilevsky, MD, PhD,
FRCPC
Queens University
Kingston, Ontario
Canada
Novel Glycosaminoglycan Precursors As Anti-Amyloid Agents
Award: $245,300
Duration: 2000 – 2003
Michael W. Wolfe, PhD
Brigham and Women’s Hospital
Boston, MA
Helical Peptidomimetics as Inhibitors of Alzheimer’s Gamma-Secretase
Award: $147,067
Duration: 2000 – 2002
Kumar Sambamurti, PhD
Medical University of
South Carolina
Charleston, SC
Evaluation of GPI-Anchored Proteins as Targets for Inhibition of Beta-Secretase
Award: $200,000
Duration: 2000 – 2002
Jack T. Rogers, PhD
Massachusetts General Hospital
Charlestown, MA
A New Translational Regulatory Target in the Alzheimer’s
APP Transcript
Award: $100,000
Duration: 2000 – 2002
Ottavio Arancio, MD, PhD
Nathan Kline Institute
Orangeburg, NY
Calpains: A Treatment of Alzheimer’s Disease
Award: $121,126
Duration: 2000 – 2001
Peter B. Reiner, VMD, PhD
Active Pass Pharmaceuticals
Vancouver, BC
Canada
Brain-Expressed ABC Transporters as Targets for
AD Therapeutics
Award: $150,000
Duration: 2000 – 2001
William S. Messer, Jr., PhD
University of Toledo
Toledo, OH
Development of Selective Muscarinic Agonists for
the Treatment of
Alzheimer’s Disease
Award: $267,066
Duration: 2000 – 2001
Lee-Way Jin, MD, PhD
University of Washington
Seattle, WA
The Amelioration of A-Beta
Aggregation and Cell Toxicity by Tricyclic Pyrone Compounds
Award: $50,000
Duration: 2000 – 2001
Ciaran M. Regan, PhD, DSc
University College Dublin
Belfield, Dublin
Ireland
Determination of the Effect of Chronic
Administration of ABS-205 on Morris Water Maze Learning in the Aged Rat
Award: $50,000
Duration: 2000
Mary L. Michaelis, PhD
University of Kansas
Lawrence, KS
Microtubule - Stabilizing
Drugs for Alzheimer’s Disease
Award: $300,248
Duration: 1999 – 2003
Jonathan D. Smith, PhD
The Cleveland Clinic Foundation Cleveland, OH
Estrogen and ApoE; Interaction and Effect on Pathogenesis
in a Mouse Model of Alzheimer’s Disease
Award: $416,130
Duration: 1999 – 2002
Avraham Fisher, PhD
Israel Institute for
Biological Research
Ness-Ziona, Israel
Novel M1 Muscarinic Agonists: From
Treatment Toward Delaying Progression of Alzheimer’s Disease
Award: $450,000
Duration: 1999 – 2002
Illana Gozes, PhD
Tel Aviv University
Tel Aviv, Israel
Israel Femtomolar-Acting Neuroprotective
Peptides: Application for Inhibition of Neurodegenerative Disease
Award: $220,000
Duration: 1999 – 2001